The trial "OPTimized Instillation of Mitomycin for Bladder Cancer Treatment" (Optima II, clinicaltrials.gov: NCT03558503) was a Phase 2b trial evaluating a nonsurgical alternative as a primary treatment for non-muscle-invasive bladder cancer (NMIBC). Patients received six weekly instillations of UGN-102, a mitomycin-containing reverse thermal gel. This is the first study to report on patientreported side effects of UGN-102.

中文翻译：

---

用于成人非肌肉浸润性膀胱癌一线治疗的化学消融凝胶 (UGN-102) 的最小患者报告副作用。

“用于膀胱癌治疗的丝裂霉素优化滴注”试验（Optima II，clinicaltrials.gov：NCT03558503）是一项 2b 期试验，评估非手术替代方案作为非肌肉浸润性膀胱癌（NMIBC）的主要治疗方法。患者每周接受六次 UGN-102 滴注，这是一种含有丝裂霉素的反向热凝胶。这是第一项报告患者报告的 UGN-102 副作用的研究。